BioCryst: Estimate-Beating Q1 But Risks Are Considerable (NASDAQ:BCRX)
NiseriN This is my second BioCryst (NASDAQ:BCRX) article, following 04/11/2022’s “BioCryst: After The Fall” (“FALL“). The downdraft referenced in the title to FALL was caused by its decision to pause enrollment in phase 2 trials for BCX9930 in treatment of diverse diseases. FALL closed with the following statement “… I fear its shares are going…